News

Armani Latimer Inspires the Alopecia Areata Community

Where Is DCC’s Armani Latimer Now? All About the Cheerleader’s Life After Hanging Up Her Uniform Armani Latimer, a retired…

NAAF President & CEO Nicole Friedland and NAAF Board of Directors Member Brett King, MD, PhD, Spotlighted by the University of California, Santa Cruz

UC Santa Cruz alumni at the forefront of alopecia research and advocacy NAAF President & CEO Nicole Friedland and NAAF…

NAAF Speaker and Advocate Abby Andrew Shares About Her Alopecia Journey with Health

Alopecia Gave Me the Freedom to Be Whoever I Want Abby Andrew, a NAAF speaker and advocate, shares her alopecia…

Researcher and patient

Q32 Bio Receives Fast Track Designation for Investigational Treatment for Alopecia Areata

Q32 Bio announced that it has received a Fast Track designation for bempikibart, its investigational treatment for alopecia areata (AA),…

Gavel

Sun Pharma’s LEQSELVI Released From Patent Litigation Hold

There was good news for Sun Pharmaceutical Industries, Ltd. (Sun Pharma) and the alopecia areata community in the form of…

Lisa Anderson, PhD, George Gondo, Nicole Friedland, Dr. Arash Mostaghimi

Alopecia Areata Took Center Stage at AAD Annual Meeting

Alopecia areata (AA) took center stage at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. NAAF…

NAAF Logo Green

LEQSELVI™ Commercial Launch Indefinitely Delayed Due to Patent Ruling

This past July, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, making it the third…

2nd Annual Walk For Alopecia Exceeds $900,000 Goal

The National Alopecia Areata Foundation (NAAF) is proud to announce its 2nd Annual Walk For Alopecia™ has exceeded its $900,000…

Challenges in Alopecia Areata and Opportunity to Drive Change

Last year, Nicole Friedland, NAAF President and CEO, participated in an expert steering committee, the Alopecia Areata Consensus Task Force,…

FDA Approves LEQSELVI™ for Adults with Severe Alopecia Areata

Today, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, marking the third FDA-approved treatment for…